Johnson & Johnson: Tracking Well Above The Industry
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
pharmaphorum19h
Sanofi wins appeal in spat with NICE over Sarclisa
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
Business Insider23h
J&J sues government agency over payment terms for 340B hospitals, STAT says
Johnson & Johnson has filed a lawsuit against the U.S. Health Resources and Services Administration over a closely watched dispute focusing on payment methods for some hospitals that participate in a ...
Genmab price target lowered to DKK 2,250 from DKK 2,500 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.
The New York Times17h
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...